MA54903A - Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 - Google Patents

Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1

Info

Publication number
MA54903A
MA54903A MA054903A MA54903A MA54903A MA 54903 A MA54903 A MA 54903A MA 054903 A MA054903 A MA 054903A MA 54903 A MA54903 A MA 54903A MA 54903 A MA54903 A MA 54903A
Authority
MA
Morocco
Prior art keywords
il18r1
kits
compositions
methods
inflammatory disease
Prior art date
Application number
MA054903A
Other languages
English (en)
Inventor
Janine Bilsborough
Dermot P Mcgovern
Stephan R Targan
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of MA54903A publication Critical patent/MA54903A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054903A 2019-02-08 2020-02-07 Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1 MA54903A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962802828P 2019-02-08 2019-02-08
US201962815223P 2019-03-07 2019-03-07

Publications (1)

Publication Number Publication Date
MA54903A true MA54903A (fr) 2021-12-15

Family

ID=71947518

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054903A MA54903A (fr) 2019-02-08 2020-02-07 Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1

Country Status (12)

Country Link
US (1) US20220056106A1 (fr)
EP (1) EP3920953A4 (fr)
JP (1) JP2022519819A (fr)
KR (1) KR20210130168A (fr)
CN (1) CN113645991A (fr)
AU (1) AU2020217793A1 (fr)
BR (1) BR112021015222A2 (fr)
CA (1) CA3127962A1 (fr)
IL (1) IL285344A (fr)
MA (1) MA54903A (fr)
MX (1) MX2021009247A (fr)
WO (1) WO2020163715A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3121162A1 (fr) 2018-11-29 2020-06-04 Cedars-Sinai Medical Center Compositions de rnaset2 et methodes de traitement les utilisant
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
WO2020232125A1 (fr) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Méthodes, systèmes et dispositifs de sélection de patient tl1a
EP4482531A1 (fr) 2022-02-23 2025-01-01 Bright Peak Therapeutics AG Immunocytokines il-18 spécifiques d'un antigène immun et leurs utilisations
KR20250047234A (ko) * 2022-08-05 2025-04-03 일루미나, 인코포레이티드 극한 수준의 유전자 발현을 유발하는 희귀 변이체를 식별하는 컴퓨터 구현 방법
WO2025219338A1 (fr) 2024-04-15 2025-10-23 Universität Zürich Inhibiteurs de card9 et leur utilisation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776731A (en) * 1996-02-21 1998-07-07 Immunex Corporation DNA encoding type-I interleukin-I receptor-like protein designated 2F1
US6087116A (en) * 1997-03-12 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin-18 (IL-18) receptor polypeptides and their uses
WO2002032374A2 (fr) * 2000-10-18 2002-04-25 Immunex Corporation Methodes de traitement de troubles induits par l'il-18
WO2006009114A1 (fr) * 2004-07-16 2006-01-26 Atsuo Sekiyama Antagoniste du recepteur il-18 et composition pharmaceutique contenant cet antagoniste
US8367333B2 (en) * 2008-12-12 2013-02-05 Decode Genetics Ehf. Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction
CN109462996A (zh) * 2016-03-17 2019-03-12 西达-赛奈医疗中心 通过rnaset2诊断炎性肠病的方法
WO2019209942A1 (fr) * 2018-04-24 2019-10-31 Cedars-Sinai Medical Center Méthodes et systèmes de caractérisation de maladie de crohn grave
HRP20231367T1 (hr) * 2018-04-30 2024-02-16 Cedars-Sinai Medical Center Postupci i sustavi za odabir i liječenje pacijenata sa upalnim bolestima
US20210220471A1 (en) * 2018-07-13 2021-07-22 Memorial Sloan Kettering Cancer Center Methods of using pharmacologic inhibitors of type 2 cytokine signaling to treat or prevent pancreatic cancer

Also Published As

Publication number Publication date
CA3127962A1 (fr) 2020-08-13
MX2021009247A (es) 2021-09-08
CN113645991A (zh) 2021-11-12
KR20210130168A (ko) 2021-10-29
EP3920953A4 (fr) 2022-12-14
BR112021015222A2 (pt) 2021-12-28
US20220056106A1 (en) 2022-02-24
EP3920953A1 (fr) 2021-12-15
JP2022519819A (ja) 2022-03-25
WO2020163715A1 (fr) 2020-08-13
AU2020217793A1 (en) 2021-09-30
IL285344A (en) 2021-09-30

Similar Documents

Publication Publication Date Title
MA54903A (fr) Méthodes, compositions et kits pour traiter une maladie inflammatoire ciblant il18r1
JOP20200115A1 (ar) تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
EP3481402A4 (fr) Composés, compositions et méthodes de traitement de maladie
EP3534907A4 (fr) Compositions et méthodes de traitement d'une maladie hépatique
EP3897747A4 (fr) Molécules bi-fonctionnelles pour le ciblage des lysosomes, compositions et méthodes associées
EP3852608A4 (fr) Compositions et méthodes destinées à traiter le glaucome
EP3675859A4 (fr) Composés, compositions et méthodes pour le traitement d'une maladie
EP3983445A4 (fr) Compositions et méthodes de traitement du cancer
EP3678640A4 (fr) Procédés et compositions pour traiter une maladie cutanée inflammatoire
EA202092086A1 (ru) Ингибиторы аргиназы
MA52208A (fr) Biomarqueurs pour une maladie du greffon contre l'hôte
EP3952914A4 (fr) Procédés et compositions pour une dégradation de protéine ciblée
WO2018098117A8 (fr) Compositions à base d'arni ciblant le gène serpina1 et leurs méthodes d'utilisation
EA201592223A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EP3817771A4 (fr) Compositions et méthodes pour traiter une maladie intestinale inflammatoire
EP2714081A4 (fr) Méthodes, compositions et trousses pour le traitement du cancer
EP3737400A4 (fr) Compositions et méthodes de ciblage de cancers exprimant clec12a
EP3710039A4 (fr) Méthodes et compositions de traitement du cancer par ciblage de la voie clec2d-klrb1
JOP20200228A1 (ar) تركيبات وطرق لخفض تعبير البروتين tau
EP3768270A4 (fr) Méthodes et compositions pour traiter une fibrose pulmonaire idiopathique
MA55093A (fr) Méthodes et compositions pour le traitement du cancer
EP3500257A4 (fr) Composés inhibiteurs de kinase, compositions et méthodes de traitement du cancer
EP4110822A4 (fr) Compositions et méthodes pour traiter le cancer
EA202091520A1 (ru) Композиции на основе irna против бокса-1 высокомобильной группы (hmgb1) и способы их применения
EA202192786A1 (ru) Твердые формы (e)-3-[2-(2-тиенил)винил]-1h-пиразола